Antivirals

Ledipasvir-Sofosbuvir Treatment for Chronic Hepatitis C Virus Infection

Ledipasvir-Sofosbuvir Treatment for Chronic Hepatitis C Virus Infection

By

Ledipasvir-sofosbuvir treatment for chronic HCV infection may be efficacious, safe, and tolerable for HCV genotype 1 and 4.

HIV Control Criteria: Overview & Expert Roundtable

HIV Control Criteria: Overview & Expert Roundtable

By

Although the overall number of new HIV infections has declined worldwide, it is estimated that 5000 new infections occur each day.

Glecaprevir/Pibrentasvir Effective, Well-Tolerated in Older HCV Patients

Glecaprevir/Pibrentasvir Effective, Well-Tolerated in Older HCV Patients

By

Due to the limited amount of published literature analyzing treatment options for older chronic HCV infection patients, the study authors aimed to determine the efficacy and tolerability of glecaprevir/pibrentasvir in this population.

Dolutegravir Plus Lamivudine Promising for HIV Maintenance Therapy

Dolutegravir Plus Lamivudine Promising for HIV Maintenance Therapy

By

For PLWHIV who achieve virologic suppression, dolutegravir plus lamivudine may be a safe and effective maintenance therapy.

Sleep Abnormalities Do Not Reverse After Discontinuing Efavirenz

Sleep Abnormalities Do Not Reverse After Discontinuing Efavirenz

By

For patients with HIV receiving efavirenz-based therapy, sleep and neuropsychological abnormalities do not readily reverse after discontinuation of treatment.

Antiretroviral Resistance Testing in People With HIV May Not Be Beneficial

Antiretroviral Resistance Testing in People With HIV May Not Be Beneficial

By

Antiretroviral drug resistance testing may not benefit people who have HIV, specifically in terms of mortality risk and disease progression.

Potential of HIV-Protective Drugs Administered Via Rectal Douches

Potential of HIV-Protective Drugs Administered Via Rectal Douches

By

Rectal douches could be a viable option to deliver HIV-protective drugs to men who practice receptive anal intercourse with other men.

Effect of HIV Pretreatment Drug Resistance on Virologic Outcomes

Effect of HIV Pretreatment Drug Resistance on Virologic Outcomes

By

Dual-class pretreatment drug resistance to first-line tenofovir/emtricitabine/efavirenz regiment may be associated with poorer virologic suppression.

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

Screening recommended for those ages 15 to 65 years, including pregnant women.

Real-World Data Show Rising HCV Epidemic Among Young Adults

Real-World Data Show Rising HCV Epidemic Among Young Adults

By

The study included 17,149,480 patients obtained from 2 national laboratory datasets who were screened between 2013 and 2016 based on an AB test.

HCV Reinfection Rates Examined Following Successful Treatment

HCV Reinfection Rates Examined Following Successful Treatment

By

In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.

HCV Treatment Linked to Reduced Risk of Incident CVD Events

HCV Treatment Linked to Reduced Risk of Incident CVD Events

By

ERCHIVES (Electronically Retrieved Cohort of HCV Infected Veterans) was utilized to identify all patients who received HCV treatment for at least 7 weeks as well as a propensity-score matched group who did not receive treatment.

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

By

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients

Direct-Acting Agents Help to Eliminate Hepatitis C in Liver Transplant Recipients

By

The introduction of DAAs has caused a significant reduction in the percentage of liver transplant recipients for HCV who are viremic after surgery.

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

By

Women with a high hepatitis B viral load who receive tenofovir during pregnancy have a significantly reduced risk for passing on the virus to their child, without an increase in the risk of adverse events.

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

DAA Treatment Combo for HCV Improves Patient-Reported Outcomes

By

An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.

Abnormal Bone Metabolism With Tenofovir for HBV Infection

Abnormal Bone Metabolism With Tenofovir for HBV Infection

By

Long-term treatment with tenofovir for hepatitis B virus infection is associated with hypophosphatemia and elevated serum levels of fibroblast growth factor 23, a hormone that induces renal phosphate excretion.

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

Anti-HBs Protect Against HBV Reactivation During Chemotherapy

By

Meta-analysis provides further support to findings that show a protective role of antibody to hepatitis B surface antigen against reactivation in patients with resolved HBV undergoing chemotherapy for hematologic tumors without antiviral prophylaxis.

Antivirals Effective in Patients With HCV Infection and Hemophilia

Antivirals Effective in Patients With HCV Infection and Hemophilia

By

A phase 2b trial showed that direct-acting antivirals were effective for treating hepatitis C virus infection in patients with inherited bleeding disorders.

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

Liver and Treatment Failure Cases Linked With Newer HCV Antivirals

By

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the cases of liver failure and antiviral failure reported to the FDA.

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

By

The 8-week regimen of LDV/SOF for HCV genotype 1 induced sustained virologic response at 12 weeks in nearly all patients treated.

Sign Up for Free e-newsletters